The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin

2014 ◽  
Vol 46 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Hólmfridur Helgadóttir ◽  
David C. Metz ◽  
Yu-Xiao Yang ◽  
Andrew D. Rhim ◽  
Einar S. Björnsson
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Therapy ◽  
Long Term Therapy

scholarly journals Iatrogenic hypomagnesemia: an underestimated clinical problem

2015 ◽  
Vol 9 (3) ◽  
pp. 287 ◽  
Author(s):  
Antonio Villa ◽  
Paolo Zanada ◽  
Adriana Pellegrino ◽  
Gabriella Nucera ◽  
Elena Martinoli ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Serum Magnesium ◽  
Concomitant Administration ◽  
Clinical Problem ◽  
Proton Pump Inhibitor Therapy ◽  
Term Therapy ◽  
Long Term Therapy ◽  
The Relationship

Hypomagnesemia is defined by having a serum magnesium level of less than 1.7 mg/dL. The magnesium balance is tightly regulated by the concerted actions of the intestine, bone and kidneys. This balance can be disturbed by a wide variety of drugs. Recently, we observed a case of severe hypomagnesemia caused by proton pump inhibitor therapy. We conducted a retrospective study of an <em>intrahospital population</em> to evaluate the prevalence of hypomagnesemia and the relationship with associated drugs. Among 181 patients with hypomagnesemia only 29 were found to have hypomagnesemia with specific causes, such as chronic diarrhea, vomiting, and so on. In the remaining patients, 120 have taken proton pump inhibitors and/or diuretics and/or metformin. Clinicians should consider proton pump inhibitors as a possible causative agent when investigating hypomagnesemia and they should be especially attentive with patients who take proton pump inhibitors, especially in cases of long-term therapy (≥1 year) and/or concomitant administration of other agents that may lower magnesium levels (<em>e.g</em>., diuretics or metformin).

Hypomagnesemia and Hypocalcemia Caused by Proton-Pump Inhibitors Long-Term Therapy

2020 ◽  
Vol 27 (6) ◽  
pp. e676-e680 ◽  
Author(s):  
Paola Cabras ◽  
Michele Anedda ◽  
Laura Caddeo ◽  
Marongiu Francesco ◽  
Mameli Antonella
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Therapy ◽  
Long Term Therapy

Long-term therapy with proton pump inhibitors is associated with decreased bone density

2009 ◽  
Vol 72 (5) ◽  
pp. 608-609 ◽  
Author(s):  
Andre Bratanic ◽  
Slaven Kokic ◽  
Izet Hozo ◽  
Igor Barisic ◽  
Visnja Kokic
Keyword(s):  
Bone Density ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Therapy ◽  
Long Term Therapy

scholarly journals Problems Associated with Deprescribing of Proton Pump Inhibitors

2019 ◽  
Vol 20 (21) ◽  
pp. 5469 ◽  
Author(s):  
Helgadottir ◽  
Bjornsson
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Adverse Drug Events ◽  
Tumor Formation ◽  
Term Therapy ◽  
Special Focus ◽  
Global Issue ◽  
Number Of Patients ◽  
Long Term Therapy

Proton pump inhibitors (PPIs) are recommended as a first-line treatment for gastroesophageal reflux disease (GERD) and other acid related disorders. In recent years, concerns have been raised about the increasing prevalence of patients on long-term PPI therapy and inappropriate PPI use. It is well known that short-term PPI therapy is generally well tolerated and safe; however, their extensive long-term use is a major global issue. One of these long-standing concerns is PPI-induced gastrin elevation secondary to hypoacidity. Hypergastrinemia is believed to play a role in rebound hyperacidity when PPIs are discontinued resulting in induced dyspeptic symptoms that might result in the reinstitution of therapy. Gastrin exerts tropic effects in the stomach, especially on enterochromaffin-like (ECL) cells, and concerns have also been raised regarding the potential progression to dysplasia or tumor formation following long-term therapy. It is well known that a substantial number of patients on long-term PPI therapy can discontinue PPIs without recurrence of symptoms in deprescribing trials. What is unknown is how sustainable deprescribing should be undertaken in practice and how effective it is in terms of reducing long-term outcomes like adverse drug events, morbidity and mortality. Moreover, there is no clear consensus on when and how deprescribing strategies should be attempted in practice. This review sought to summarize the harms and benefits of long-term PPI therapy with special focus on gastrin elevation and its relation to deprescribing studies and future interventions that may improve PPI use.

Su1813 The Effects of Long-Term Therapy With Proton Pump Inhibitors (PPIs) on Meal Stimulated Gastrin

2013 ◽  
Vol 144 (5) ◽  
pp. S-480
Author(s):  
Holmfridur Helgadottir ◽  
David C. Metz ◽  
Andrew D. Rhim ◽  
Yu-Xiao Yang ◽  
Einar Bjornsson
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Therapy ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document